On June 25, 2015 Peregrine Pharmaceuticals reported that the European Patent Office (EPO) has granted Patent Number 2,269,656, titled "Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer" (Press release, Peregrine Pharmaceuticals, JUN 25, 2015, View Source [SID:1234505806]). This important patent covers bavituximab as a composition of matter and for use in treating cancer including in combination with radiotherapy or chemotherapy, such as with docetaxel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new patent covers bavituximab as a composition of matter, a range of related antibodies, including humanized and chain-shuffled antibodies and other sequence variations and their broad use in any diagnosis or therapy. The new patent also covers antibody drug conjugates, diagnostic and imaging constructs, liposomal and pharmaceutical combinations of bavituximab and related antibodies.

Know more, wherever you are:
Latest on Antibodies in Oncology, book your free 1stOncology demo here.

"This is a key part to our European patent strategy for bavituximab and an important addition to our intellectual property portfolio, which now numbers more than 140 worldwide issued patents and pending applications for our bavituximab oncology program," said Shelley Fussey, vice president of intellectual property at Peregrine. "The granting of this patent enhances the ongoing expansion and strengthening of the company’s intellectual property portfolio surrounding its immuno-oncology pipeline and our commitment to executing future global strategic collaborations and partnerships."

This patent currently provides intellectual property rights in validated European countries through July, 2023 and could be eligible for extension of patent term under the European Union’s Supplementary Protection Certificate (SPC) process. This patent was granted to The University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals.

Peregrine’s lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer (the SUNRISE trial) along with several investigator-sponsored trials evaluating additional oncology indications. The Company is also advancing its plans to initiate additional bavituximab clinical trials, including a Phase II trial in non-small cell lung cancer in combination with Opdivo (Nivolumab) and a Phase II/III trial in locally advanced or metastatic HER2 negative breast cancer in combination with either docetaxel or paclitaxel.

Peregrine’s antibodies target and bind to phosphatidylserine (PS), a highly immunosuppressive molecule normally located on the interior of cellular membranes, but, following stresses in the tumor environment, becomes exposed on tumor cells and cells that line tumor blood vessels, helping tumors to evade immune detection. PS-targeting antibodies block this immunosuppressive signal, thereby enabling the immune system to better recognize and fight the tumor. Preclinical data show that the combination of bavituximab and inhibitors of immune checkpoints reduce tumor-suppressive factors including myeloid-derived suppressor cells and confer increased tumor-specific immunity when compared to either treatment alone.